HIV Infections Clinical Trials in San Francisco, California

8 studies are recruiting for hiv infections in San Francisco, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706

   The clinical schedule will consist of 3 injections of CD40.HIVRI.Env (VRIPRO) at weeks 0, 4, and 24.40 volunteers without HIV and in overall good health, aged 18 to 60 years, who previously participated in the HVTN 706 trial.

   Stage

   Phase 1

   Ages

   18 to 60

   Site

   Bridge HIV CRS, San Francisco, California

   Locations

   9 in total

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT06665646 on ClinicalTrials.gov

2. SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era

   SCOPE is an observational, prospective study of HIV-1 infected volunteers designed to provide a specimen bank of samples with carefully characterized clinical data. SCOPE specimens will be used to examine multiple questions involving virologic, immunologic, and host factors involved in HIV-1 infect…

   Stage

   Not phased

   Ages

   18 and older

   Site

   San Francisco General Hospital, San Francisco, California

   Run by

   University of California, San Francisco

   See if you can join NCT00187512 on ClinicalTrials.gov

3. Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

   The goal of this clinical study is to compare how effective a long-acting injectable treatment of lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) versus (CAB) and rilpivirine (RPV) injections given every 8 weeks in adults with HIV-1 whose virus is well controlled on daily oral treatment…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Optimus Medical Group, San Francisco, California

   Locations

   19 in total

   Run by

   Gilead Sciences

   See if you can join NCT07682961 on ClinicalTrials.gov

4. CAR-T Cells for HIV Infection

   This is a limited-center, open-label dose escalating phase I/IIa study of autologous T cells expressing LVgp120duoCAR molecules in people with HIV infection. It will follow a 3+3 design. Dose escalation decisions will be made when a minimum of three participants have completed the safety-evaluation…

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   Zuckerberg San Francisco General, San Francisco, California

   Locations

   2 in total

   Run by

   Steven Deeks

   See if you can join NCT04648046 on ClinicalTrials.gov

5. Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)

   This is a randomized placebo-controlled study in treated and suppressed HIV-infected individuals aged ≥40 years with either known CVD or 1 CVD risk factor to study the effect of Bempedoic acid (BA) on safety, arterial inflammation as assessed by FDG-PET/CT, lipids, inflammation, immune activation, …

   Stage

   Phase 2

   Ages

   40 and older

   Site

   San Francisco General Hospital, San Francisco, California

   Locations

   3 in total

   Run by

   Priscilla Hsue, MD

   See if you can join NCT05488431 on ClinicalTrials.gov

6. Feasibility of HPV Testing With Mail-delivered Sample Collection Kits

   People living with human immunodeficiency virus (PLWH) have an estimated 1.6-6.0 times increased risk of developing oropharyngeal cancer (OPC) compared with individuals in the general population. 70% of OPCs are caused by human papillomavirus (HPV), and PLWH also have an increased prevalence of ora…

   Stage

   Not phased

   Ages

   35 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   University of California, San Francisco

   See if you can join NCT07087145 on ClinicalTrials.gov

7. Imaging Immune Activation in HIV by PET-MR

   This is a single center exploratory imaging study involving one intravenous microdose of [18F]F-AraG followed by whole-body positron emission tomography-magnetic resonance (PET-MR) imaging in HIV infected individuals to determine the anatomical distribution of the PET tracer. Participants will be e…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   CellSight Technologies, Inc.

   See if you can join NCT03684655 on ClinicalTrials.gov

8. Comparing Mobile Health Strategies to Improve Pre-exposure Prophylaxis Use (PrEP) for HIV Prevention

   The purpose of this study is to compare the effectiveness of two mobile health technologies (text messaging or a mobile app) designed to help people take HIV pre-exposure prophylaxis (PrEP) as directed by the clinic. PrEP is the use of a daily anti-HIV medications by HIV-negative people to help pre…

   Stage

   Not phased

   Ages

   15 and older

   Site

   San Francisco AIDS Foundation, San Francisco, California

   Locations

   4 in total

   Run by

   Public Health Foundation Enterprises, Inc.

   See if you can join NCT04855773 on ClinicalTrials.gov